BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Kidney Transplantation - Dr. Frederieke Bemelman\, Head of Kidney 
 transplants\, Hospital of Amsterdam (AMC)\, Netherlands
DTSTART:20101203T140000Z
DTEND:20101203T150000Z
UID:TALK26616@talks.cam.ac.uk
CONTACT:Erika Eiser
DESCRIPTION:The prevalence of end stage renal failure (ESRD) is growing ra
 pidly\, due to the ageing of the population as well as to the increase of 
 diabetes and cardiovascular diseases. Renal transplantation is the treatme
 nt of choice for patients with ESRD. As compared to dialysis patients\, re
 nal transplant recipients become older\, have a better quality of live\, a
 nd more often have a job. In addition\, the costs of transplantation are f
 ar less than those of chronic dialysis treatment. Due to the shortage of p
 ost mortal kidney donors\, a variety of programs for live donation have be
 en developed. The outcome of live donor transplantation is more successful
  as compared to post mortal donation\, especially when the recipient can b
 e transplanted just prior to the start of hemo-dialysis. However\, as comp
 ared to the normal population\, the live expectancy of renal transplant pa
 tients is still less as compared to the normal population. In addition\, t
 hey suffer from a significant co-morbidity such as cardiovascular events\,
  infections and malignancies\, partly mediated by the side effects of the 
 immunosuppressive drugs. Therefore\, research is warranted to minimize exp
 osure to these drugs. The holy grail in transplantation remains to reprogr
 am the immune system in such a way that a state of transplantation toleran
 ce will be achieved.
LOCATION:Pippard Lecture Theatre\, Cavendish Laboratory
END:VEVENT
END:VCALENDAR